α-干扰素治疗慢性乙型肝炎后TGF-β_1及肝纤维化指标的变化观察  

CHANGES IN SERUM TGF-β_1 AND HEPATIC FIBROGENESIS MARKERS AFTER INTERFERON-α THERAPY IN PATIENTS WITH CHRONIC HEPATITIS B

作　　者：王卫兵[1] 刘健虎[1] 王春莉[1] 袁福兵[1] 韩永年[2] 

机构地区：[1]解放军第101医院,无锡214044 [2]上海市血液中心,上海200051

出　　处：《中国现代医学杂志》2002年第6期69-70,共2页China Journal of Modern Medicine

摘　　要：目的探讨IFN -α对慢性乙型病毒肝炎抗肝纤维化的治疗作用。方法 :血清TGFβ1检测采用酶联免疫吸附试验法 ,HA、LN和PCⅢ测定均采用放射免疫法。结果 :治疗前两组患者的血清TGFβ1、HA、LN和PCⅢ无显著性差异 (P >0 .0 5 ) ,治疗组在治疗后TGFβ1、HA、LN和PCⅢ都比治疗前有明显下降 (P <0 .0 1) ,而对照组治疗前后统计学无意义 (P >0 .0 5 )。且HBeAg转阴率与对照组比较有显著性差异 (P <0 .0 5 )。结论 :IFN -α具有一定的抗肝纤维化作用。Objective:To investigate the effect of interferon-α(IFN-α) on liver fibrosis formation of chronic hepatitis B. Method:Serum TGF-β1 was detected by ELISA.Serum levels of hyaluronic acid (HA)?laminin(LN)?and type Ⅲ procollagen (PCⅢ) were detected by radioimmunoassay.Results:Between the two groups,the serum levels of TGF-β1?HA?LN and PCⅢ were of no significant difference before treatment with IFN-α( P > 0.05 ).In the treatment group,after treatment with IFN-α,the serum levels of TGF-β1?HA?LN and PCⅢ significantly decreased compared to the ones before treatment ( P <0.01),while the control group was of no significance ( P > 0.05 ).The negative-convertion rates of HBeAg were significance in the two groups( P <0.05).Conclusions:IFN-α has better efficacy to liver fibrosis formation of chronic hepatitis B.

关 键 词：Α-干扰素 慢性乙型病毒性肝炎 转化生长因子β1 肝纤维化 治疗 转阳率 酶联免疫吸附法 

分 类 号：R512.62[医药卫生—内科学] R977.6[医药卫生—临床医学]